Nov 11, 2013
Zacks Upgrades Ultrapar Participacoes SA to Neutral
The firm currently has a $25.30 price target on the stock. Zacks ' price objective indicates a potential upside of 2.64% from the stock's previous close.
Ultrapar Participacoes' Management Discusses Q3 2013 Results - Earnings Call Transcript
Good afternoon ladies and gentlemen. At this time, we would like to welcome everyone to Ultrapar's 3Q13 Results Conference Call.
Ultrapar announces its 3Q13 results
"We are very pleased to announce today a period of great achievements, which were made possible by the investments in strengthening and developing our businesses and by a corporate governance structure designed to align interests and to endure the company and its growth.
The Washington Post
Drugstore Billionaire Open to CVS Partnership: Corporate Brazil
Empreendimentos Pague Menos SA, Brazil's second-biggest drugstore company, would consider U.S. partners such as CVS Caremark Corp. and Walgreen Co.